title: Samarium Sm 153 lexidronam for the palliative treatment of dogs with primary bone tumors: 35 cases (1999-2005).
abstract: OBJECTIVE
  To evaluate survival times and palliative effects associated with the use of samarium Sm 153 lexidronam in dogs with primary bone tumors.
  
  
  METHODS
  Retrospective case series.
  
  
  METHODS
  35 dogs with primary appendicular (n = 32) or axial (3) bone tumors.
  
  
  METHODS
  1 to 4 doses of samarium Sm 153 lexidronam were administered at a rate of 37 MBq/kg (16.8 MBq/lb), IV. Response to treatment, measured by lameness improvement, and survival time were determined.
  
  
  RESULTS
  Of the 32 dogs with appendicular tumors, 20 (63%) had an improvement in the severity of lameness 2 weeks after administration of the first dose of radioactive samarium, 8 (25%) had no change in the severity of lameness, and 4 (12%) had a worsening. Overall median survival time was 100 days, with 3 dogs (8.6%) alive after 1 year. Median survival time for the 32 dogs with appendicular tumors was 93 days, with 3 (9.4%) alive after 1 year. This was not significantly different from the median survival time of 134 days for a historical cohort of 162 dogs with appendicular osteosarcoma that underwent amputation as the only treatment.
  
  
  CONCLUSIONS
  Results suggest that samarium Sm 153 lexidronam may be useful in the palliation of pain in dogs with primary bone tumors that are not candidates for curative-intent treatment.
authors.affiliation: Gladesville Veterinary Hospital, 449 Victoria Rd, Gladesville, NSW 2111, Australia.
authors.forename: Sandra M
authors.initials: SM
authors.lastname: Barnard
authors.forename: R Max
authors.initials: RM
authors.lastname: Zuber
authors.forename: Antony S
authors.initials: AS
authors.lastname: Moore
mesh_terms: D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use*; D000818:Animals; D001859:Bone Neoplasms / Q000150:complications / Q000628:therapy / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D010166:Palliative Care / Q000379:methods*; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018712:Analgesics, Non-Narcotic; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; C061972:samarium Sm-153 lexidronam